.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Healthtrust
McKesson
Dow
Deloitte
Citi
Chinese Patent Office
Medtronic
Harvard Business School

Generated: November 24, 2017

DrugPatentWatch Database Preview

Desvenlafaxine succinate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for desvenlafaxine succinate and what is the scope of desvenlafaxine succinate freedom to operate?

Desvenlafaxine succinate
is the generic ingredient in two branded drugs marketed by Alembic Pharms Ltd, Zydus Pharms Usa Inc, Sandoz Inc, Actavis Labs Fl, Lupin Ltd, West-ward Pharms Int, Wyeth Pharms Inc, and Mylan Pharms Inc, and is included in nine NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.

There are sixteen drug master file entries for desvenlafaxine succinate. Twelve suppliers are listed for this compound.

Medical Subject Heading (MeSH) Categories for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204095-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Actavis Labs Fl
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204065-001Jul 29, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204172-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204172-002Jun 29, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204082-001Feb 16, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204020-001Oct 11, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-001Feb 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Sandoz Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204028-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204082-002Aug 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-001Feb 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: desvenlafaxine succinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: desvenlafaxine succinate

Country Document Number Estimated Expiration
Slovenia1360169► Subscribe
Hong Kong1057885► Subscribe
European Patent Office2319826► Subscribe
Denmark1360169► Subscribe
TaiwanI318201► Subscribe
Australia782092► Subscribe
China1501909► Subscribe
New Zealand539791► Subscribe
MexicoPA03007043► Subscribe
South Korea20030077614► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Harvard Business School
Chubb
Cipla
McKinsey
Mallinckrodt
Express Scripts
Medtronic
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot